Compare Gilead Sciences, Inc. (GILD) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $133.19 (market cap $163.51B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $96.04. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| GILD | JNK | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $98.19 |
52-Week Low | $108.22 | $94.66 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JNK trades at $96.09 with minimal daily movement (+0.2%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators remain neutral. The ETF continues its dividend payments with recent distributions of $0.52-$0.53 per share. Market sentiment reflects uncertainty around Federal Reserve policy and inflation concerns, creating volatility in high-yield bond markets.
The outlook for JNK remains challenged by rising interest rate expectations and inflation pressures. While the ETF offers attractive yield, investors face headwinds from potential Fed tightening and market volatility. Key risks include interest rate sensitivity and credit quality concerns in the high-yield bond space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
